Exeltis   Report issue

Contributed to NME For profit Phase 3 Phase 4
Founded: Florham Park NJ United States (1971)

Organization Overview

First Clinical Trial
2018
NCT03739541
First Marketed Drug
2003
estradiol (progynon depot)
First NDA Approval
2017
benznidazole (Rochagan)
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Chemo Research | Chemo Research SL | Chemo Research S.L. | CHEMO RESEARCH SL | Exeltis | Exeltis France | Exeltis Turkey | Exeltis USA | EXELTIS USA INC | XIROMED